Esbriet

June 3, 2020June 3, 2020

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

Esbriet, News

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not treated with such therapies, a large registry-based study ... Read more

May 27, 2020May 27, 2020

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Esbriet, News

A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF). The study “A multicentre retrospective observational study on ... Read more

November 5, 2019November 5, 2019

PROOF Real-world Data Continues to Show Esbriet’s Ability to Preserve Lung Function in IPF

Esbriet, News

Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results ... Read more

September 10, 2019September 11, 2019

Real-world Esbriet Results Are Comparable to Those of Clinical Trials, Study Says

Esbriet, News

Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in clinical trials, a new study shows. “Pirfenidone in real life: ... Read more

August 16, 2019August 16, 2019

Taking Esbriet for IPF Does Not Increase Risk of Heart Problems, Analysis Says

Esbriet, News

Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of ... Read more

June 19, 2019June 21, 2019

Esbriet Helps Halt Breathlessness Symptoms in Severe IPF, Analysis of Multiple Trials Shows

Esbriet, News

Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF), a post-hoc analysis of the ASCEND and CAPACITY trials shows. The ... Read more

April 8, 2019

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Esbriet, News

Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, ... Read more

March 26, 2019April 4, 2019

Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests

Esbriet, News

A post-hoc analysis of the Phase 3 RECAP trial shows that long-term treatment with Esbriet (pirfenidone) is safe and similarly effective in patients with advanced idiopathic pulmonary fibrosis (IPF) as in ... Read more

January 30, 2019February 5, 2019

Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals

Esbriet, News

Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study ... Read more

January 23, 2019January 31, 2019

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Esbriet, News

The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be ... Read more

Pin It on Pinterest